Literature DB >> 12242590

Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors.

Victoria Tovar1, Juana del Valle, Nuria Zapater, Margarita Martin, Xavier Romero, Pilar Pizcueta, Jaime Bosch, Cox Terhorst, Pablo Engel.   

Abstract

Human CS1, also known as novel Ly9, 19A24, or CRACC, is a member of the immunoglobulin gene superfamily (IgSF) expressed on natural killer cells and other leukocytes. Here we describe the cloning of the mouse homologue of this gene. The mouse novel Ly9 gene is shown to encode a transmembrane protein composed of two extracellular immunoglobulin-like domains, a transmembrane region and an 88-amino acid cytoplasmic domain. Mouse novel Ly9 is structurally similar to the extracellular domains of CD84 and CD229 (Ly9). Both mouse and human novel Ly9 genes mapped close to the CD229gene in a region where other members of the CD150 family have also been mapped, and analysis of their genomic sequences showed that they have an identical intron/exon organization. Northern blot analysis revealed that the expression of mouse and human novel Ly9 was predominantly restricted to hematopoietic tissues, with the exception of testis. Here we show that SAP (SH2D1A), an adapter protein responsible for the X-linked lymphoproliferative disease, binds to the phosphorylated cytoplasmic tail of human but not mouse novel Ly9. Taken together, these data indicate that mouse novel Ly9 is a new member of the expanding CD150 family of cell surface receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12242590     DOI: 10.1007/s00251-002-0483-3

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  8 in total

1.  An epistatic effect of the female specific loci on the development of autoimmune vasculitis and antinuclear autoantibody in murine lupus.

Authors:  M-C Zhang; N Misu; H Furukawa; Y Watanabe; M Terada; H Komori; T Miyazaki; M Nose; M Ono
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

2.  Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function.

Authors:  Mario-Ernesto Cruz-Munoz; Zhongjun Dong; Xiaochu Shi; Shaohua Zhang; André Veillette
Journal:  Nat Immunol       Date:  2009-01-18       Impact factor: 25.606

Review 3.  The involvement of immunoglobulin superfamily proteins in spermatogenesis and sperm-egg interaction.

Authors:  Kiyotata Toshimori; Mamiko Maekawa; Chizuru Ito; Yoshiro Toyama; Fumie Suzuki-Toyota; Dinesh K Saxena
Journal:  Reprod Med Biol       Date:  2006-05-19

4.  Alternative splicing and mRNA expression analysis of bovine SLAMF7 gene in healthy and mastitis mammary tissues.

Authors:  Zhihua Ju; Changfa Wang; Qiuling Li; Minghai Hou; Shuai Gao; Qinlei Hou; Jianbin Li; Jinming Huang; Jifeng Zhong
Journal:  Mol Biol Rep       Date:  2011-07-17       Impact factor: 2.316

Review 5.  SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions.

Authors:  Cynthia Detre; Marton Keszei; Xavier Romero; George C Tsokos; Cox Terhorst
Journal:  Semin Immunopathol       Date:  2010-02-10       Impact factor: 9.623

6.  Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.

Authors:  Djordje Atanackovic; Jens Panse; York Hildebrandt; Adam Jadczak; Sebastian Kobold; Yanran Cao; Julia Templin; Sabrina Meyer; Henrike Reinhard; Katrin Bartels; Nesrine Lajmi; Axel R Zander; Andreas H Marx; Carsten Bokemeyer; Nicolaus Kröger
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

Review 7.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

8.  Fine specificity and molecular competition in SLAM family receptor signalling.

Authors:  Timothy J Wilson; Lee I Garner; Clive Metcalfe; Elliott King; Stefanie Margraf; Marion H Brown
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.